Literature DB >> 8660360

Regulation of growth, PSA/PAP and androgen receptor expression by 1 alpha,25-dihydroxyvitamin D3 in the androgen-dependent LNCaP cells.

T Y Hsieh1, C Y Ng, C Mallouh, H Tazaki, J M Wu.   

Abstract

The involvement of vitamin D in prostate carcinogenesis was investigated using the human prostatic LNCaP cells. Incubation of the LNCaP with 100 nM 1 alpha,25-dihydroxyvitamin D3 for 2 days resulted in a 30-40% suppression of cell growth, which was accompanied by a greater than 70% down-regulated expression of the proliferating cell nuclear antigen (PCNA). The intracellular and secreted forms of PSA showed a 2-fold increase following a 48 h culture in the presence of vitamin D3. The vitamin D3-elicited PSA increases were preceded by an induction of androgen receptor (AR) expression, as measured by Western blot analysis and by binding assays using [3H]R1881 as the ligand. These results are consistent with the hypothesis that the growth inhibitory effects of vitamin D3 is partially mediated through its ability to modulate PCNA expression. Moreover, vitamin D3 may effect increases in PSA expression indirectly by up-regulating androgen receptors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8660360     DOI: 10.1006/bbrc.1996.0859

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

Review 1.  New trial designs to assess antitumor and antiproliferative agents in prostate cancer.

Authors:  Walter Stadler
Journal:  Invest New Drugs       Date:  2002-05       Impact factor: 3.850

2.  Elevated cyclin E levels, inactive retinoblastoma protein, and suppression of the p27(KIP1) inhibitor characterize early development of promyeloid cells into macrophages.

Authors:  Q Liu; R W VanHoy; J H Zhou; R Dantzer; G G Freund; K W Kelley
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

3.  Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey.

Authors:  Steven L Chang; Lauren C Harshman; Joseph C Presti
Journal:  J Clin Oncol       Date:  2010-08-02       Impact factor: 44.544

4.  Interleukin-1α mediates the antiproliferative effects of 1,25-dihydroxyvitamin D3 in prostate progenitor/stem cells.

Authors:  Sophia L Maund; Wendy W Barclay; Laura D Hover; Linara S Axanova; Guangchao Sui; Jason D Hipp; James C Fleet; Andrew Thorburn; Scott D Cramer
Journal:  Cancer Res       Date:  2011-06-08       Impact factor: 12.701

5.  Androgen Receptor regulation of Vitamin D receptor in response of castration-resistant prostate cancer cells to 1α-Hydroxyvitamin D5 - a calcitriol analog.

Authors:  Benjamin Mooso; Anisha Madhav; Sherra Johnson; Mohana Roy; Mary E Moore; Christabel Moy; Grace A Loredo; Rajendra G Mehta; Andrew T M Vaughan; Paramita M Ghosh
Journal:  Genes Cancer       Date:  2010-11-16

Review 6.  The role of vitamin D in reducing cancer risk and progression.

Authors:  David Feldman; Aruna V Krishnan; Srilatha Swami; Edward Giovannucci; Brian J Feldman
Journal:  Nat Rev Cancer       Date:  2014-04-04       Impact factor: 60.716

7.  TRPV6 determines the effect of vitamin D3 on prostate cancer cell growth.

Authors:  V'yacheslav Lehen'kyi; Maylis Raphaël; Agathe Oulidi; Matthieu Flourakis; Sergii Khalimonchyk; Artem Kondratskyi; Dmitri V Gordienko; Brigitte Mauroy; Jean-Lois Bonnal; Roman Skryma; Natalia Prevarskaya
Journal:  PLoS One       Date:  2011-02-11       Impact factor: 3.240

Review 8.  Vitamin D, intermediary metabolism and prostate cancer tumor progression.

Authors:  Wei-Lin W Wang; Martin Tenniswood
Journal:  Front Physiol       Date:  2014-05-15       Impact factor: 4.566

9.  25-Hydroxyvitamin D and TSH as Risk Factors or Prognostic Markers in Thyroid Carcinoma.

Authors:  Debora Lucia Seguro Danilovic; Bruno Ferraz-de-Souza; Amanda Wictky Fabri; Nathalie Oliveira Santana; Marco Aurelio Kulcsar; Claudio Roberto Cernea; Suemi Marui; Ana Oliveira Hoff
Journal:  PLoS One       Date:  2016-10-13       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.